All In Biotech

Drug Trial Radar · NCT07824869

A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients

A Multicenter, Randomized, Double-Blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX22 in Combination With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy in Locally Advanced Unresectable and/or Metastatic HER2-Positive Breast Cancer Previously Treated With HER2 ADC

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Oct 31, 2026

Primary completion

Mar 31, 2028

Study completion Dec 4, 2029

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Sep 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II study of HLX22 in combination with trastuzumab and chemotherapy versus placebo in combination with trastuzumab and chemotherapy in locally advanced and/or metastatic HER2-Positive breast cancer previously treated with HER2 ADC. Eligible participants will be treated with the study drug until the loss of clinical benefit, intolerable toxicity, initiation of new anti-tumor therapy, voluntary withdrawal from the study by the patient, loss to follow-up, death, or when the investigator determines that the patient should be withdrawn from the study (whichever occurs first).

Conditions

  • HER2 + Breast Cancer

Interventions

  • HLX22Drug

    15 mg/kg, intravenous infusion (IV) on Day 1 (D1) of Q3W

  • TrastuzumabDrug

    Loading dose 8 mg/kg, maintenance dose 6 mg/kg, IV, Q3W, D1.

  • CapecitabineDrug

    1000 mg/m2, oral (po), twice daily (BID), D1-14, Q3W

  • PaclitaxelDrug

    175 mg/m2, D1; or 80-90 mg/m2, D1 D8 D15, Q3W, IV

  • DocetaxelDrug

    75-100 mg/m2, D1, Q3W, IV

  • EribulinDrug

    1.4 mg/m2, D1 and D8, Q3W, IV

  • VinorelbineDrug

    25-30 mg/m2, D1 and D8, Q3W, IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) assessed by the blinded independent central review (BICR) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Time frame: Up to 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.